| Followers | 831 |
| Posts | 120081 |
| Boards Moderated | 16 |
| Alias Born | 09/05/2002 |
Saturday, February 16, 2008 6:41:53 PM
IDX899 vs The Field in HIV
This slide shows how IDX899 potency compares to
selected HIV drugs in short monotherapy studies. The
number of days of treatment is shown at the bottom of
each bar; the number below each bar is the mean log
reduction in viral load at study end. All patients were
treatment-naïve genotype-1.
From left to right, the displayed bars are:
IDX899 (IDIX, phase-2)
Sustiva (marketed by BMY/MRK)
Intelence (marketed by JNJ)
TMC278 (JNJ, entering phase-3)
UK 453,061 (PFE, phase-2)
Raltegravir (MRK, phase-3)
Selzentry (marketed by PFE)
Reyataz (marketed by BMY)
Viread (marketed by GILD)
3TC (marketed by GSK)
The footnotes indicate that the displayed results for Sustiva and Intelence are not from the doses that were eventually approved by the FDA, so these figures should not be taken too literally; however, the main message of the slide is that IDX899 can at least hold its own on potency vs its key competitors in the HIV arena.
Insofar as IDX899 is a non-nucleoside reverse-transcriptase inhibitor (NNRTI), the most important competitors are Sustiva, Intelence, and TMC278. Raltegravir, Selzentry, Reyataz, Viread, and 3TC work by different MoA’s, while UK 453,061 appears to have hit a bump in the road (#msg-26610262).
This slide shows how IDX899 potency compares to
selected HIV drugs in short monotherapy studies. The
number of days of treatment is shown at the bottom of
each bar; the number below each bar is the mean log
reduction in viral load at study end. All patients were
treatment-naïve genotype-1.
From left to right, the displayed bars are:
IDX899 (IDIX, phase-2)
Sustiva (marketed by BMY/MRK)
Intelence (marketed by JNJ)
TMC278 (JNJ, entering phase-3)
UK 453,061 (PFE, phase-2)
Raltegravir (MRK, phase-3)
Selzentry (marketed by PFE)
Reyataz (marketed by BMY)
Viread (marketed by GILD)
3TC (marketed by GSK)
The footnotes indicate that the displayed results for Sustiva and Intelence are not from the doses that were eventually approved by the FDA, so these figures should not be taken too literally; however, the main message of the slide is that IDX899 can at least hold its own on potency vs its key competitors in the HIV arena.
Insofar as IDX899 is a non-nucleoside reverse-transcriptase inhibitor (NNRTI), the most important competitors are Sustiva, Intelence, and TMC278. Raltegravir, Selzentry, Reyataz, Viread, and 3TC work by different MoA’s, while UK 453,061 appears to have hit a bump in the road (#msg-26610262).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
